Company intelligence / Profile preview
GammaCan International
Givat Shmuel, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
GammaCan developed an IVIg-based anti-cancer immunotherapy candidate ("GCAN101") with promising preclinical results for reducing metastases and recurrence in cancer. The company aimed to initiate Phase II trials but there are no public records indicating successful advancement beyond this stage or commercial approval. The company appears inactive as of the latest available information.
- Therapeutic areas
- OtherOncology
- Modalities
- AntibodyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on GammaCan International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GammaCan International.